Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology

Chronic myelogenous leukemia (CML) is a malignancy of the myeloid cell lineage characterized by a recurrent chromosomal abnormality: the Philadelphia chromosome, which results from the reciprocal translocation of the chromosomes 9 and 22. The Philadelphia chromosome contains a fusion gene called BCR...

Full description

Bibliographic Details
Main Authors: Vlad Moisoiu, Patric Teodorescu, Lorand Parajdi, Sergiu Pasca, Mihnea Zdrenghea, Delia Dima, Radu Precup, Ciprian Tomuleasa, Simona Soverini
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukemia
mathematical modeling
BCR-ABL
IS
treatment free remission
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00863/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00863/full

Similar Items